A Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma (CTCL)

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-001076-18

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective is to determine the overall cutaneous response rate (RR) based on the modified Severity Weighted Assessment Tool (mSWAT) criteria.


Critère d'inclusion

  • Stage Ib-IVa Cutaneous T-cell Lymphoma